A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

Enriqueta Felip; Margarita Majem; Bernard Doger; Timothy Clay; Enric Carcereny; Igor Bondarenko; Julio Peguero; Manuel Cobo-Dols; Martin Forster; Grygorii Ursol; Gema Ledo; Laia Vilà; Matthew Krebs; Wade Iams; Christian Mueller; Frederic Triebel

doi:10.1200/JCO.2022.40.16_suppl.9003

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

Enriqueta Felip, Margarita Majem, Bernard Doger, Timothy Clay, Enric Carcereny, Igor Bondarenko, Julio Peguero, Manuel Cobo-Dols, Martin Forster, Grygorii Ursol, Gema Ledo, Laia Vilà, Matthew Krebs, Wade Iams, Christian Mueller, Frederic Triebel

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	9003
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
DOIs	https://doi.org/10.1200/JCO.2022.40.16_suppl.9003
Publication status	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2022.40.16_suppl.9003

Cite this

Felip, E., Majem, M., Doger, B., Clay, T., Carcereny, E., Bondarenko, I., Peguero, J., Cobo-Dols, M., Forster, M., Ursol, G., Ledo, G., Vilà, L., Krebs, M., Iams, W., Mueller, C., & Triebel, F. (2022). A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population. Journal of Clinical Oncology, 40, 9003. https://doi.org/10.1200/JCO.2022.40.16_suppl.9003

@article{9ca6617020c14d89b498b7d7bee15b63,

title = "A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.",

author = "Enriqueta Felip and Margarita Majem and Bernard Doger and Timothy Clay and Enric Carcereny and Igor Bondarenko and Julio Peguero and Manuel Cobo-Dols and Martin Forster and Grygorii Ursol and Gema Ledo and Laia Vil{\`a} and Matthew Krebs and Wade Iams and Christian Mueller and Frederic Triebel",

year = "2022",

month = jun,

day = "1",

doi = "10.1200/JCO.2022.40.16_suppl.9003",

language = "English",

volume = "40",

pages = "9003",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

Felip, E, Majem, M, Doger, B, Clay, T, Carcereny, E, Bondarenko, I, Peguero, J, Cobo-Dols, M, Forster, M, Ursol, G, Ledo, G, Vilà, L, Krebs, M, Iams, W, Mueller, C & Triebel, F 2022, 'A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.', Journal of Clinical Oncology, vol. 40, pp. 9003. https://doi.org/10.1200/JCO.2022.40.16_suppl.9003

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population. / Felip, Enriqueta; Majem, Margarita; Doger, Bernard et al.
In: Journal of Clinical Oncology, Vol. 40, 01.06.2022, p. 9003.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

AU - Felip, Enriqueta

AU - Majem, Margarita

AU - Doger, Bernard

AU - Clay, Timothy

AU - Carcereny, Enric

AU - Bondarenko, Igor

AU - Peguero, Julio

AU - Cobo-Dols, Manuel

AU - Forster, Martin

AU - Ursol, Grygorii

AU - Ledo, Gema

AU - Vilà, Laia

AU - Krebs, Matthew

AU - Iams, Wade

AU - Mueller, Christian

AU - Triebel, Frederic

PY - 2022/6/1

Y1 - 2022/6/1

U2 - 10.1200/JCO.2022.40.16_suppl.9003

DO - 10.1200/JCO.2022.40.16_suppl.9003

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

SP - 9003

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -